

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7185368

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
STRONGBRIDGE DUBLIN LIMITED	02/18/2022
RECEIVING PARTY DATA	
Name:	XERIS PHARMACEUTICALS, INC.
Street Address:	180 N. LASALLE STREET, SUITE 1600
City:	CHICAGO
State/Country:	ILLINOIS
Postal Code:	60601
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	9918984
Patent Number:	10098877
Patent Number:	10517868
Patent Number:	10835530
Patent Number:	11020393
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-371-2600
Email:	dsterling@sternekessler.com, tarjahn@sternekessler.com, dcolonna@sternekessler.com
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
Address Line 1:	1100 NEW YORK AVENUE, N.W.
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	4605.0930003
NAME OF SUBMITTER:	DEBORAH STERLING #62,732
SIGNATURE:	/Deborah Sterling #62,732/
DATE SIGNED:	02/18/2022
Total Attachments: 3	
source=4605-Assignment-Strongbridge-to-Xeris#page1.tif	

source=4605-Assignment-Strongbridge-to-Xeris#page2.tif

source=4605-Assignment-Strongbridge-to-Xeris#page3.tif

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, **STRONGBRIDGE DUBLIN LIMITED**, having a business address of 900 Northbrook Drive, Suite 200, Trevose, Pennsylvania 19503 (hereafter referred to as the "Assignor"), hereby sells and assigns to **XERIS PHARMACEUTICALS, INC.**, a corporation formed under the laws of Delaware, having an office and place of business at 180 N. LaSalle Street, Suite 1600, Chicago, Illinois 60601 (hereafter referred to as the "Assignee"), its entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world, including the right to sue for past infringement and to collect for all past, present and future damages,

(a) in each of the Patents and Patent Applications that are described in detail in Schedule A, annexed hereto and made a part hereof, and

(b) in any and all applications that claim the benefit of the Patents and Patent Applications described in detail in Schedule A, including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals, and reexaminations of such Patents and Patent Applications, to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in each of the Patents and Patent Applications that are described in detail on Schedule A, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such Patents and Patent Applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the applications and Letters Patents as above, and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding applications thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant

proceeding, patent enforcement action (judicial or otherwise) related to the applications or Letters Patents or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such judicial or administrative proceeding.

The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee.


The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment, including the attached Schedule A, any further information regarding the patents and patent applications so identified in such Schedule A that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned Assignor hereby represents that the Assignor understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are legal representatives of, and attorneys for, the Assignee, and are NOT the legal representatives of, and attorneys for, the Assignor.


SIGNED on behalf of the said ASSIGNOR,

STRONGBRIDGE DUBLIN LIMITED

By: 
Name: Beth Hecht
Title: Chief Legal Officer & Corporate Secretary
Date: Feb 18, 2022

SIGNED on behalf of the said ASSIGNEE,

XERIS PHARMACEUTICALS, INC.

By: 
Name: Brian J. Del Buono
Title: Chief Intellectual Property Counsel
Date: February 18, 2022

SCHEDULE A

UNITED STATES PATENTS, UNITED STATES PATENT APPLICATIONS

Application No.	Filing Date	Patent No.	Issue
15/088,539	April 1, 2016	9,918,984	March 20, 2018
15/886,437	February 1, 2018	10,098,877	October 16, 2018
16/152,202	October 4, 2018	10,517,868	December 31, 2019
16/715,690	December 16, 2019	10,835,530	November 17, 2020
17/010,387	September 2, 2020	11,020,393	June 1, 2021

17977671.1